APA (7th ed.) Citation

Mulhern, C. M., Hong, Y., Omoyinmi, E., Jacques, T. S., D'Arco, F., Hemingway, C., . . . Eleftheriou, D. (2019). Janus kinase 1/2 inhibition for the treatment of autoinflammation associated with heterozygous TNFAIP3 mutation. Journal of allergy and clinical immunology, 144(3), 863-866.e5. https://doi.org/10.1016/j.jaci.2019.05.026

Chicago Style (17th ed.) Citation

Mulhern, Ciara M., Ying Hong, Ebun Omoyinmi, Thomas S. Jacques, Felice D'Arco, Cheryl Hemingway, Paul A. Brogan, and Despina Eleftheriou. "Janus Kinase 1/2 Inhibition for the Treatment of Autoinflammation Associated with Heterozygous TNFAIP3 Mutation." Journal of Allergy and Clinical Immunology 144, no. 3 (2019): 863-866.e5. https://doi.org/10.1016/j.jaci.2019.05.026.

MLA (9th ed.) Citation

Mulhern, Ciara M., et al. "Janus Kinase 1/2 Inhibition for the Treatment of Autoinflammation Associated with Heterozygous TNFAIP3 Mutation." Journal of Allergy and Clinical Immunology, vol. 144, no. 3, 2019, pp. 863-866.e5, https://doi.org/10.1016/j.jaci.2019.05.026.